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Background: Late side-effects are becoming an important issue in non-Hodgkin’s lymphoma (NHL) survivors. We
intended to estimate pooled relative risk (RR) of secondary malignant neoplasms (SMNs), to evaluate site-associated
RR and the impact of different treatments.
Design: We carried out an electronic search of Medline and EMBASE seeking articles investigating the risk of SMNs
and reporting RR measures. The studies were evaluated for heterogeneity before meta-analysis and for publication
bias. Pooled RRs were estimated using fixed- and random-effects models.
Results: A total of 23 studies met the inclusion criteria. Pooled RRs of SMNs overall and for solid tumors were 1.88
and 1.32, respectively. We found an excess of risk for several specific cancer sites. Radiotherapy alone did not
increase the risk for SMNs, while chemotherapy and combined treatments augmented the RR. Regression analyses
revealed a positive significant association for all SMNs with total body irradiation, and for solid SMNs with younger age.
No publication bias was observed.
Conclusions: Our results indicate that NHL patients experience a higher risk for SMNs than the general population
and that various treatments have different impact on RR. More information will be necessary to evaluate possible
interactions with genetic susceptibility and environmental exposure.
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introduction
Chemotherapy with or without radiation therapy has been the
mainstay of non-Hodgkin’s lymphoma (NHL) treatment. In
the past few years, evolving therapies have led to improved
long-term survival for some histological subtypes, and the
introduction of monoclonal antibody treatments has further
improved the prognosis of indolent [1–3] and aggressive [4–8]
B-cell NHL. High-dose chemotherapy followed by autologous
stem-cell transplantation (ASCT) and allogeneic bone marrow
transplantation has emerged as another promising approach for
the treatment of relapsed lymphoma or as part of planned
treatment of neoplasm with a poor prognosis [9–12]. As a
result of these advances, the prevalence of NHL survivors is
expected to increase and late side-effects of treatment such as
secondary malignant neoplasms (SMNs) are becoming an
important issue.
Carcinogenesis linked to specific tumor sites was highlighted
as a late effect associated with exposure to chemotherapeutic
drugs [13–18] or radiotherapy [15, 19–21] as single-modality
therapy, or combined-modality approaches including
conventional-dose chemotherapy with radiotherapy [22] or
with total body irradiation (TBI) [23], ASTC following high-
dose chemotherapy [24–26], and TBI used in the preparative
regimen for ASTC [27]. Nevertheless, several studies have failed
to detect a significant relationship between therapy exposure
and SMNs, probably because the estimation was often based on
a small number of patients. Although several previous
descriptive literature reviews [28–35] have discussed the risk for
a second cancer, overall risk for therapy-related SMNs is less
certain and the comparison of SMNs risk for NHL survivors
with a general population yielded conflicting results among the
studies.
Therefore, we carried out this meta-analysis to provide a
quantitative assessment on the risk for SMNs. The purposes
were to estimate the pooled relative risk (RR) of SMNs overall
and for solid tumors, to evaluate the site-associated RR, and to
examine the risk linked to treatment modality.
methods
This meta-analysis was carried out according to the guidelines proposed by
the Meta-Analysis of Observational Studies in Epidemiology group [36].
We did not carry out methodological quality assessment of the studies
because quality scoring in meta-analysis is controversial [37], ad hoc scores
can fail validation, and results may not be associated with quality [36, 38].
In place of a subjective quality score, we carried out subgroup and
sensitivity analyses [36].
o
ri
g
in
a
l
a
rt
ic
le
*Correspondence to: Dr R. Marcheselli, Department of Oncology and Hematology,
University of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy. Tel:
+39-059-4222175; Fax: +39-059-4224152; E-mail: raffaella.marcheselli@unimore.it
ª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com
 at U
niversitÃ degli Studi di M
odenae Reggio Emilia on December 4, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Studies were reviewed and data extracted and cross-checked
independently by two reviewers (RM and MP); disagreements were resolved
by consensus with another author (LM).
search strategy
We identified studies of interest by first conducting an electronic literature
search of the databases Medline and EMBASE. We used exploded Medical
Subject Heading terms ‘lymphoma, non-Hodgkin’, ‘lymphoma, t-cell’, and
‘lymphoma, b-cell’. The terms were combined with ‘neoplasm, second
primary’ using the Boolean operator ‘and’. In the second step, these
keywords were combined using the Boolean operator ‘and’ with the terms
‘standardized incidence ratio’, ‘observed to expected’, and ‘standardized
morbidity ratio’. In addition, we reviewed the reference lists of relevant
studies to identify additional relevant published articles.
selection criteria
We included studies that met each of following criteria: (i) published in
English language between January 1985 and December 2008; (ii) included
naive patients with any stage of NHL; (iii) investigated the risk for SMNs in
NHL survivors; (iv) reported RR, specified as standardized incidence ratios
or data allowing such outcomes to be derived; and (v) published as original
papers (no reviews, comments, letters, or editorials).
Of the studies on specific NHL histologies, we excluded hairy cell
leukemia and chronic lymphocytic leukemia because in population-based
studies, these diseases are normally classified as leukemia. When two or
more articles reported duplicate data, we included the most recently
updated data or most informative study.
data extraction
A standardized form was used for each study included in the meta-analysis.
Extracted data included paper characteristics (first author’s last name,
publication year, country in which the study was carried out, and data
source), study design, number of NHL patients, histological subtype, mean/
median age of patients, duration of follow-up, therapy, number of cases
observed with SMNs and expected number of cases, and/or RR with
corresponding 95% confidence interval (CI). Where not reported, we
computed the CI for the RR assuming a Poisson distribution for the
observed number of cases. Standard error (SE) for the natural logarithm of
RR [ln(RR)] was derived from CI, applying the following equation: SE =
ln(upper 95% CI/lower 95% CI)/(2 · z1 2 a/2).
Figure 1. Flow chart of literature search. SIR, standardized incidence ratio; RR, relative risk; NHL, non-Hodgkin’s lymphoma.
original article Annals of Oncology
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Table 1. Characteristics of studies included in the meta-analysis
Study
(reference)
Country Source of
data, study
period
No. of cases of
primary NHL,
histology
Treatment Median age
at diagnosis,
years
Median
follow-up
No. of
secondary
malignancies
All
malignancies
RR (95% CI)
No. of
solid
tumors
Solid
tumors
RR (95% CI)
Data from clinical trials
Barista
et al. 2002 [71]
United
States
Two M.D.
Anderson
trials,
1994–2000
156, mantle
cell
Hyper-CVAD/
M-A 6
TBI 6 SCT
59.5 26
months
7 100.0
(49.3–186.6)
– –
Andre´
et al. 2004 [17]
France Three GELA
trials,
1984–1998
947 F and
1320 M,
aggressive
NHL
CHOP-
like 6 RT
54 74
months
22 Fa, 44 Ma 0.94
(0.59–1.42),
0.92 (0.67–1.24)
14 Fa, 35 Ma 0.63
(0.35–1.06),
0.77 (0.54–1.07)
Moser
et al. 2006 [72]
Four
European
Countries
Four EORTC
trials,
1980–1999
748, aggressive
NHL
CHOP-like 6
RT 6 SCT
49b 8.9
years
– – 37b 1.0 (0.7–1.3)
Mudie
et al. 2006 [18]
UK BNLI,
1973–2000
2456, B-cell
histologies
Alk, CHOP 6
RT, RT
alone
46.5b 7.7
yearsb
123a 1.3 (1.1–1.6) 103a 1.1 (0.9–1.4)
Sacchi
et al. 2008 [73]
Italy GISL trials,
1988–2003
563, indolent
NHL
Alk 6
anthracycline 6
fludarabine 6
RT
60 62
months
39 1.9 (1.4–2.7) – –
Sacchi
et al. 2008 [74]
Italy GISL trials,
1988–2003
1280, diffuse
large B cell
PBC, CHOP,
CHOP-like 6
RT
58 51
months
48 1.1 (0.8–1.5) – –
Data from hospital- or specialist center-based studies
Takenaka
et al. 1985 [75]
Japan National
Cancer
Center
Hospital,
1962–1983
407, various
histologies
Combined
CHT 6 RT,
RT alone,
surgery 6
combined
CHT 6 RT
50 – 11 1.0 (0.50–1.81c) – –
Lavey
et al. 1990 [76]
United
States
Duke University
Medical
Center,
1970–1981
686, various
histologies
CHOP-like 6
RT, RT aloned
54.6 5.5
years
48 0.8 (0.5–1.1) 39 0.6 (0.4–0.9)
Lishner
et al. 1991 [77]
Canada Princess
Margaret
Hospital,
1970–1985
3021, various
histologies
WW, Alk,
combined
CHT6 RT
59 4
years
119 1.0 (0.8–1.2) – –
Travis
et al. 1996 [23]
United
States
Harvard Joint
Center,
1965–1980
61, various
histologies
Low-dose
TBI 6
Alk 6 RT
50 8.6
years
12 2.8 (1.5–4.9) 8 2.0 (0.9–4.0)
A
n
n
a
ls
o
f
O
n
c
o
lo
g
y
o
rig
in
a
l
a
rtic
le
V
o
lu
m
e
2
2
|N
o
.
8
|A
u
g
u
st
2
0
1
1
d
o
i:1
0
.1
0
9
3
/a
n
n
o
n
c
/m
d
q
6
9
7
|
1847
 at UniversitÃ degli Studi di Modenae Reggio Emilia on December 4, 2015 http://annonc.oxfordjournals.org/ Downloaded from 
Table 1. (Continued)
Study
(reference)
Country Source of
data, study
period
No. of cases of
primary NHL,
histology
Treatment Median age
at diagnosis,
years
Median
follow-up
No. of
secondary
malignancies
All
malignancies
RR (95% CI)
No. of
solid
tumors
Solid
tumors
RR (95% CI)
Tanaka
et al. 1997 [78]
Japan Osaka Medical
Center,
1978–1994
592, various
histologies
Combined
CHT 6 RT,
RT alone
56.3b 3.7 yearsb 27 1.53 (1.01–2.23) 24 1.42
(0.91–2.11c)
Leung
et al. 2001 [79]
United
States
St Jude Hospital,
1970–1997
497, various
histologies
Poorly
described
10.7 13.6 years 16 10.8 (6.1–16.9) 9 6.7
(3.0–11.9)
Brown
et al. 2005 [27]
United
States
DFCI, 1982–1997 605, B-cell
histologies
Combined
CHT +
Alk +
TBI + ASTC
44 9.5 years 116b 6.43 (5.31–7.71c) – –
Guadagnolo
et al. 2006 [80]
United
States
Harvard area
hospitals,
1972–2000
106, follicular
(stages I–II)
RT, TBI 6
combined
CHT
55 12 years 14 1.56 (0.85–2.61c) – –
Iannitto
et al. 2006 [81]
Italy Three Italian
hospitals,
1988–2003
129, splenic
marginal
zone B –cell
WW, surgery,
Alk, purine
analogs
65 32.6 months 12b 2.03 (1.05–3.56) – –
Arcaini
et al. 2007 [82]
Italy 2 Italian
hospitals,
1991–2004
157, nongastric
MALT
WW, surgery,
Alk,
CHOP 6 RT
64 3 years 9b 1.32 (0.69–2.55) – –
Bluhm
et al. 2008 [21]
United
States
CCSS, 1970–1986 1082, various
histologies
Combined
CHT
(included
CHOP-like) 6
RT 6 SCT 6
surgery,
RT alone
10 17 yearsb 31 3.5 (2.4–5.0) 27 3.9 (2.6–5.7)
Data from population-based studies
Greene and
Wilson 1985 [83]
United
States
Connecticut CR,
1935–1982
6734, various
histologies
Poorly
described
58b 4 yearsb 319 1.24 (1.11–1.39) – –
Brennan
et al. 2005 [84]
11 countries 13 CRs,
1943–2000
109 451,
various
histologies
Poorly
described
Data in class Data in
class
6673 1.47 (1.43–1.51) – –
Tward
et al. 2006 [19]
United
States
CRs of SEER
Program,
1973–2001
77 823,
various
histologies
Poorly
described
61 60 months 6188 1.14 (1.11–1.17) 5363 1.11 (1.08–1.14)
Hemminki
et al. 2008 [85]
Sweden Swedish
Family-Cancer
Database
linked to
Swedish CR, 1961–
2004
29 134,
various
histologies
CHOP 6
RT 6 ASCT,
RT alone
Data in class Data in
class
– – 2290 1.65 (1.59–1.72)
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Table 1. (Continued)
Study
(reference)
Country Source of
data, study
period
No. of cases of
primary NHL,
histology
Treatment Median age
at diagnosis,
years
Median
follow-up
No. of
secondary
malignancies
All
malignancies
RR (95% CI)
No. of
solid
tumors
Solid
tumors
RR (95% CI)
Study included for specific cancer sites
Levi
et al. 1996 [86]
Switzerland CR of Swiss
Canton,
1974–1993
1767, various
histologies
Poorly
described
43.5b 4.2 yearsb – – – –
Dores
et al. 2006 [87]
United
States
CRs of SEER
Program,
1973–2000
73 958,
various
histologies
Poorly
described
Data in class Data in
class
– – – –
aExcept nonmelanoma skin cancer (Mudie et al. [18] excluded also NHL as secondary malignancy).
bMean.
cThe 95% CI was computed assuming a Poisson distribution of observed number of cases.
dThe study by Lavey et al. [76] included a part of patients that did not receive anthracycline.
NHL, non-Hodgkin’s lymphoma; RR, relative risk; CI, confidence interval; Hyper-CVAD/M-A, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternated with methotrexate
and cytosine arabinoside; TBI, total body irradiation; SCT, stem-cell transplantation; GELA, Groupe d’Etudes des Lymphomes de l’Adulte; F, female; M, male; CHOP, cyclophosphamide, doxorubicin,
vincristine, and prednisone; RT, radiotherapy treatment; EORTC, European Organisation for Research and Treatment of Cancer; BNLI, British National Lymphoma Investigation; Alk, alkylating (including
chlorambucil, cyclophosphamide, carmustine, and melphalan); GISL, Gruppo Italiano Studio Linfomi; PBC, ProMECE-CytaBOM (methylprednisolone, cyclophosphamide, epidoxorubicin or doxorubicin,
etoposide, cytarabine, bleomycin, vincristine, methotrexate); CHT, chemotherapy; WW, watch and wait; DFCI, Dana-Farber Cancer Institute; ASTC, autologous stem-cell transplantation; MALT, extranodal
marginal zone lymphoma of mucosa-associated lymphoid tissue; CCSS, Childhood Cancer Survivor Study; CR, Cancer Registry; SEER, Surveillance, Epidemiology, and End Results.
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Cancer sites with at least three RR estimates meeting our meta-analysis
criteria are reported separately. When studies showed that the observed
number of cases was zero, we simply added 1 to both the observed and the
expected number of cases to enable computation of an estimate of the
ln(RR) and its associated SE [39]. Some authors were contacted for
clarification and additional and unreported information for the meta-
analysis.
statistical analysis
Statistical heterogeneity of RR across the studies was explored with the
Cochran’s Q test [40] and I2 statistic [41, 42]. A P value >0.10 for the Q
statistic and an I2 value <50% was interpreted as signifying a low level of
heterogeneity. The pooled estimates of RR, together with associated 95%
CIs, were obtained using the DerSimonian and Laird random-effects model
[43] and the Mantel–Haenszel fixed-effects model [44], according to
heterogeneity statistics.
For the principal meta-analysis, we calculated pooled RR, associated with
95% CIs with fixed and random effects to evaluate the effects of any small
studies [45].
Publication bias was sought using the funnel plots and quantified using
the rank correlation test as proposed by Begg and Mazumdar [46] and
the regression asymmetry test by Egger et al. [47]. All statistical tests were
Figure 2. Forest plot of the meta-analysis relating risk for secondary malignancy in non-Hodgkin’s lymphoma survivors. Squares represent the relative risk
of each single study (size of the square reflects the study-specific statistical weight); horizontal lines represent 95% confidence intervals (CIs); diamonds
represent the pooled estimates, based on the random-effects meta-analysis of the studies, with corresponding 95% CIs. F, female; M, male.
Table 2. Meta-analysis of risk for overall secondary malignancy and overall solid tumors in non-Hodgkin’s lymphoma survivors
Type of study Model used No. of studies (reference) Q test (P value) I2, % RR 95% CI
Secondary malignancy
Clinical trial Fixed effects 6 [17F, 17M, 18, 71, 73, 74] <0.001 97.1 1.43 1.26–1.62
Random effects 6 [17F, 17M, 18, 71, 73, 74] <0.001 97.1 2.36 1.08–5.14
Hospital- or specialist
center-based study
Fixed effects 11 [21, 23, 27, 75–82] <0.001 96.2 2.42 2.19–2.69
Random effects 11 [21, 23, 27, 75–82] <0.001 96.2 2.11 1.18–3.77
Population-based study Fixed effects 3 [19, 83, 84] <0.001 98.8 1.29 1.26–1.31
Random effects 3 [19, 83, 84] <0.001 98.8 1.27 1.04–1.56
Overall study Fixed effects 20 [17F, 17M–19, 21, 23, 27, 75–84] <0.001 97.5 1.31 1.29–1.34
Random effect 20 [17F, 17M–19, 21, 23, 27, 75–84] <0.001 97.5 1.88 1.58–2.22
Solid tumors
Overall study Fixed effects 10 [17F, 17M, 18, 19, 21, 23, 76, 78,
79, 85]
<0.001 97.2 1.25 1.23–1.29
Random effect 10 [17F, 17M, 18, 19, 21, 23, 76, 78,
79, 85]
<0.001 97.2 1.32 1.07–1.63
Pooled relative risks (RRs) and relative 95% confidence intervals (CIs) were from fixed or random models. F, female; M, male.
original article Annals of Oncology
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two-sided. One-way sensitivity analysis was used to investigate the influence
of each study on the overall estimate by calculating a pooled RR omitting
each estimate one at a time [48]. Additionally, subgroup sensitivity analysis
was carried out to evaluate the robustness of results. Meta-regressions were
fitted by restricted maximum likelihood algorithm. The ln(RR) was the
dependent variable, and the characteristics analyzed included type of data
source (clinical trials, hospital- or specialist center-based studies, and
population-based studies), average age of NHL patients (median or mean),
average period of calendar recruitment of patients, and follow-up duration
(<5 years, ‡5 years); for the meta-regression on all malignancies, we took
into account the exposure of patients to TBI (as a dummy variable). We
first conducted a univariate regression analysis for each factor, followed by a
multivariate regression (including only the studies for which the factors of
interest were available). A permutation test was applied to fitted models to
establish the true statistical significance of a positive finding, incorporating
20 000 Monte Carlo simulations [49].
Statistical analyses were carried out using the Stata software package,
version 10.1 (StataCorp, College Station, TX).
results
search results
We initially identified 1521 potentially eligible studies (Figure 1).
After exclusion of duplicate references, nonrelevant literature,
and papers that did not satisfy inclusion criteria, 47 candidate
articles remained for further review. The full text of these
articles was carefully read, and 24 candidate papers were
excluded due to overlapping publications or nonsatisfaction of
inclusion criteria [14, 15, 20, 50–70].
We used a total of 23 studies for the meta-analyses. Of these,
21 studies contributed to principal meta-analysis on the risk for
SMNs and/or solid SMNs: 6 were studies from clinical trials
[17, 18, 71–74], 11 were studies carried out in hospitals or
specialist centers [21, 23, 27, 75–82], and 4 were population-
based studies, i.e. based on data from cancer registries [19, 83–
85]. Nineteen studies were identified that provided risks for
specific cancer types [17–19, 21, 23, 27, 72, 74–79, 81, 83–87].
Two studies were included in the meta-analysis, although they
partially overlapped other papers. The study by Hemminki
et al. [85] was included because it covered a recent time period
(1999–2004) not present in the previous large study by Brennan
et al. [84]. The paper of Dores et al. [87], a chapter in a
multiauthored book, was included in our meta-analysis for the
specific cancer sites not reported in a subsequent article [19].
The main features of the studies included in the meta-analysis
and the estimated RR with 95% CIs are showed in Table 1.
meta-analysis results
overall secondary malignancy risk. The analyzed dataset
encompassed 19 articles (Table 1). Studies included a total of
208 643 NHL survivors who developed 13 878 SMNs recruited
during the period 1935–2004. Twelve studies [18, 19, 21, 23, 27,
71, 73, 78, 79, 81, 83, 84] reported positive association between
risk for SMNs and previous NHL, whereas 7 [17, 74–77, 80, 82]
showed no association. The statistical heterogeneity tests
yielded highly significant results (Cochran’s Q test, P < 0.001;
I2 = 97.5%) giving evidence of statistical heterogeneity. Figure 2
presents the results of the random-effects model meta-analysis.
The pooled RR of SMNs was 1.88 (95% CI 1.58–2.22), an
increased, statistically significant value in comparison with the
risk of the general population. The pooled RRs calculated from
each subgroup (for clinical trials, hospital-based studies, and
population-based studies, RRs were 2.36, 2.11, and 1.28,
respectively) were significant. The pooled RR of SMN using the
fixed-effect model was 1.31 (95% CI 1.29–1.34) (Table 2) and
showed that any small-study effects had little impact on the
intervention effect estimate.
The funnel plot was symmetric (data not shown), and the
Begg–Mazumdar and Egger test results provided no evidence of
publication bias.
Sensitivity analyses demonstrated the substantial stability of
our results (Figure 3A). However, excluding the study by Barista
et al. [71] that reported a very high RR, we found a lower pooled
RR for all malignancies (RR = 1.63; 95% CI 1.40–1.91), and the
subanalysis on studies carried out on patients from clinical trials
showed no excess of risk (RR = 1.20; 95% CI 0.95–1.52).
A meta-regression analysis showed a significant positive
association between ln(RR) and the follow-up ‡5 years (P = 0.038)
and exposure to TBI (P = 0.002). After correction for multiple
testing, only exposure to TBI was found significant (P = 0.014).
overall solid tumors risk. We did not carry out a meta-analysis
for solid SMNs according to the type of studies because the
Figure 3. Sensitivity analysis conducted for meta-analysis on risk for
overall (A) and solid (B) secondary malignancy. Pooled relative risks and
95% confidence intervals were calculated by omitting each study in turn. F,
female; M, male.
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number of available articles was limited. A total of 10 studies
encompassing 115 916 NHL patients, recruited from 1961 to
2004, were included in the analysis (Table 1), and 7949 patients
developed solid SMNs. Two population-based studies [19, 85]
and two institutional studies [21, 79] reported a significant
positive association for the risk for solid SMNs and previous
NHL. The statistical tests indicated substantial heterogeneity
across the studies (Cochran’s Q test, P < 0.001; I2 = 97.2%).
Meta-analysis carried out on all studies showed a significant
association between previous NHL and the risk for solid SMNs
(Figure 4); the random-effects combined estimate resulted in
an RR of 1.32 (95% CI 1.07–1.63). The pooled RR of SMN
using the fixed-effect model was 1.25 (95% CI 1.23–1.29)
(Table 2) and showed that any small-study effects had little
impact on the intervention effect estimate. Neither Egger’s nor
Begg–Mazumdar’s test supported publication bias.
Sensitivity analysis (Figure 3B) showed that the omission in
turn of each study did not appreciably change the pooled RR,
and the estimates in each case were within the CI of the pooled
estimate.
By regression analysis, we identified a significant association
between young age at diagnosis (P = 0.011). Following a
permutation test in multivariate analysis, age was revealed
as having a significant influence on the ln(RR) of SMNs
(P = 0.024).
site-specific incidence. Table 2 summarizes the meta-analysis
results by cancer site. The 19 papers available for analysis were
published between 1985 and 2008; of these, 4 present data from
clinical trials [17, 18, 72, 74], 9 were hospital-based studies [21,
23, 27, 75–79, 81] and 5 were population-based studies [19, 83–
86]. The majority of investigated sites manifested a statistically
significant RR increase for solid tumors in comparison with the
reference population (Table 3). For corpus uteri, we found a
significant negative association with primary NHL. Among
lymphohematopoietic tumors, we did not discover significant
differences with respect to the general population for second
primary NHL, while an excess of risk was observed for multiple
myeloma, Hodgkin’s lymphoma, leukemia, and
nonlymphocytic leukemia. Publication bias was not evident
when the Begg and the Egger tests were used.
impact of different treatments. Table 4 presents the pooled RRs
according to treatment modality. The use of any type of
chemotherapy alone was associated with higher risk for SMNs.
A similar result was observed in the subanalysis on patients
treated only with alkylating agents, while the pooled RR of
SMNs for patients who underwent treatment with
cyclophosphamide, adriamycin, vincristine, and prednisone
(CHOP) or CHOP-like or radiotherapy alone was raised but
not statistically significant. A combined modality of treatment
was significantly associated with the risk for overall SMNs but
not for solid tumors.
In addition, we evaluated the effect of TBI exposure limiting
the analysis to the studies that explicitly described the therapies.
We examined the association between TBI exposure and overall
Figure 4. Forest plot of the meta-analysis relating risk for secondary solid tumors in non-Hodgkin’s lymphoma survivors. Squares represent the relative risk
of each single study (size of the square reflects the study-specific statistical weight); horizontal lines represent 95% confidence intervals (CIs); diamonds
represent the pooled estimates, based on the random-effects meta-analysis of the studies, with corresponding 95% CIs. F, female; M, male; CT, data from
clinical trials; HB, data from hospital- or specialist center-based studies; PB, data from population-based studies.
original article Annals of Oncology
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Table 3. Meta-analysis of risk for selected cancer sites in NHL survivors
Second primary malignancy No. of studies (reference) No. of primary NHL Heterogeneity statistics Model used Pooled effect
Q test (P value) I2, % RR 95% CI
Solid tumors
Tongue 4 [77, 83, 84, 87] 193 164 0.148 43.9 Fixed effects 1.67 1.24–2.25
Salivary gland 5 [77, 83–85, 87] 222 298 0.473 0.0 Fixed effects 2.02 1.50–2.71
Oropharynx 3 [77, 84, 87] 186 430 0.317 12.9 Fixed effects 2.11 1.41–3.16
Esophagus 6 [18, 19, 77, 83–85] 228 619 0.161 36.8 Fixed effects 1.16 0.99–1.37
Stomach 9 [18, 19, 23, 75, 77, 78,
83–85]
229 679 0.510 0.0 Fixed effects 1.33 1.22–1.44
Colon 5 [18, 19, 77, 83, 84] 199 485 0.030 62.7 Random effects 1.16 1.00–1.33
Rectum 6 [18, 19, 23, 77, 83, 84] 199 546 0.504 0.0 Fixed effects 1.03 0.93–1.13
Liver 5 [19, 78, 83–85] 223 734 0.001 79.6 Random effects 1.47 1.05–2.07
Pancreas 8 [18, 19, 72, 77,
78, 83–85]
229 959 0.036 53.2 Random effects 1.16 0.92–1.45
Nose and nasal cavity 3 [84, 85, 87] 212 543 0.012 77.6 Random effects 2.78 1.36–5.65
Larynx 5 [77, 83–85, 87] 222 298 0.888 0.0 Fixed effects 1.20 1.00–1.43
Lung 12 [17a–19, 27, 72, 74 ,77,
78, 81, 83–85]
233 293 0.001 64.5 Random effects 1.53 1.36–1.73
Soft tissue 6 [18, 19, 27, 77, 83, 84] 200 090 0.108 44.6 Fixed effects 2.14 1.76–2.59
Melanoma 7 [18, 19, 27, 77, 83–85] 230 991 0.032 54.4 Random effects 1.85 1.54–2.23
Bone 5 [18, 21, 83, 84, 87] 193 681 0.338 11.9 Fixed effects 3.49 2.43–4.99
Eye 3 [83, 84, 87] 190 143 0.359 2.3 Fixed effects 1.45 0.95–2.22
Brain 6 [19, 21, 77, 83–85] 227 245 <0.001 83.9 Random effects 1.84 1.18–2.87
Thyroid 7 [19, 21, 27, 72, 83–85] 225 577 <0.001 84.5 Random effects 3.55 1.92–6.55
Breast (female) 12 [17a–18, 19, 21,
23, 27, 72, 74, 77, 83–85]
235 232 <0.001 81.7 Random effects 1.10 0.88–1.37
Uterine cervix 6 [18, 77, 83–85, 87] 224 754 0.289 19.1 Fixed effects 1.06 0.85–1.32
Uterine corpus 6 [18, 77, 83–85, 87] 224 754 0.134 40.7 Fixed effects 0.85 0.75–0.97
Ovary 7 [18, 27, 78, 83–85, 87] 222 930 0.309 15.8 Fixed effects 1.03 0.89–1.19
Prostate 11 [18, 19, 23, 27,
72, 74, 77, 78, 83–85]
231 905 0.001 66.8 Random effects 1.05 0.91–1.20
Testis 4 [19, 77, 83, 84] 197 029 0.175 39.5 Fixed effects 1.78 1.18–2.69
Bladder 11 [18, 19, 21, 27,
72, 77, 78, 81, 83–85]
231 775 0.038 47.9 Fixed effects 1.42 1.33–1.52
Lymphohematopoietic tumors
Myeloma multiple 6 [18, 19, 77, 83–85] 228 619 0.006 69.4 Random effects 1.74 1.60–1.89
Hodgkin’s lymphoma 7 [18, 19, 72, 77, 83–85] 229 367 <0.001 87.7 Random effects 7.00 3.84–12.73
NHL 3 [83, 85, 87] 109 826 <0.001 98.7 Random effects 1.63 0.50–5.32
Leukemia 6 [18, 19, 72, 78, 83, 85] 117 487 <0.001 97.0 Random effects 3.21 1.51–6.83
Nonlymphocytic leukemia 9 [18, 23, 76–79, 83, 84, 87] 197 456 <0.001 96.1 Random effects 11.1 4.67–26.25
Pooled RRs and relative 95% CIs were from fixed- or random-effects models according to the results of Cochran’s Q test and the I2 value. The pooled-RR in bold were statistically significant.
aThe study by Andre´ et al. [17] reported a lung cancer RR for men only.
NHL, non-Hodgkin’s lymphoma; RR, relative risk; CI, confidence intervals.
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Table 4. Stratified analysis of pooled relative risks (RR) of second malignancy according to treatment
Treatment No. of studies (reference) Heterogeneity statistics Model used Pooled effect
Q test (P value) I2, % RR 95% CI
Chemotherapy, any type of drugsa,b
All malignancies 7 [18, 19, 73–76, 78] <0.001 80.5 Random effect 1.49 1.11–2.10
Solid tumors 3 [18, 19, 76] 0.317 13.1 Fixed effect 1.10 1.07–1.13
Alkylatingb
All malignancies 2 [18, 73] 0.802 0.0 Fixed effect 1.43 1.07–1.90
Solid tumors 0
CHOP or CHOP-likeb
All malignancies 4 [17, 18, 74, 76c] <0.001 84.0 Random effect 1.28 0.79–2.05
Solid tumors 3 [17, 21, 76c] <0.001 91.1 Random effect 1.16 0.58–2.30
Radiotherapy, only therapy
All malignancies 4 [18, 75, 76, 78] <0.898 0.0 Fixed effect 1.18 0.84–1.64
Solid tumors 2 [18, 76] <0.514 0.0 Fixed effect 1.23 0.88–1.70
Additional radiotherapy to any type of chemotherapy
All malignancies 8 [18, 19, 73–76, 78, 80d] <0.001 77.6 Random effect 1.50 1.03–2.20
Solid tumors 5 [18, 19, 21, 72, 80d] <0.001 87.5 Random effect 1.29 0.87–1.92
aThe analysis on any type of chemotherapy presents the results derived from studies for which we were able to trace the RR only for this type of therapy; thus, we did not include the RR calculated in the studies
by Andre´ et al. 2004 [17], Bluhm et al. [21], and Moser et al. [72] because a part of patients was treated also with radiotherapy.
bThe RR reported in the studies used to estimate the pooled RR for specific chemotherapeutic agents (alkylating and CHOP or CHOP-like) can include a proportion of patients undergoing radiotherapy.
cThe study by Lavey et al. [76] included a part of patients that did not receive Anthracycline.
dThe study by Guadagnolo et al. [80] was included among studies analyzed in the group of patients treated with local radiotherapy after chemotherapy because only six patients (6%) received extended-field
radiotherapy or low-dose total body irradiation.
RR, relative risk; CI, confidence interval; CHOP, cyclophosphamide, adriamycin, vincristine, and prednisolone. The pooled-RR in bold were statistically significant.
o
rig
in
a
l
a
rtic
le
A
n
n
a
ls
o
f
O
n
c
o
lo
g
y
1854
|
P
ira
n
i
e
t
a
l.
V
o
lu
m
e
2
2
|N
o
.
8
|A
u
g
u
st
2
0
1
1
 at UniversitÃ degli Studi di Modenae Reggio Emilia on December 4, 2015 http://annonc.oxfordjournals.org/ Downloaded from 
risk for SMNs using the RR reported in each study,
discriminating on the basis of the proportion of patients
undergoing TBI (Figure 5). We found a significantly increased
risk for SMNs for exposed and unexposed patients; however,
the risk estimated among the studies including patients
undergoing TBI was higher.
discussion
This meta-analysis was designed to estimate the risk for SMNs
in patients with a history of NHL. Our goals were to evaluate
the RR for overall and solid SMNs, to assess site-associated RR,
and to estimate the risk related to treatment modality. We
showed that NHL survivors face a 1.88-fold increased risk for
SMNs in comparison with the general population. When the
analysis was restricted to solid tumors, we also observed an
increased risk that resulted associated with younger age of
patients. A statistically significant increase in risk was also
found for several specific cancer types. Finally, we assessed
association between treatment exposure and risk for SMNs,
although we could not explore this aspect in detail because
treatment information was ill described for some studies as also
chemotherapy dose schedule. We found evidence of effects to
exposure to chemotherapeutic agents, especially alkylating
agents, alone or in combination with radiotherapy.
Furthermore, a stronger association with risk for SMNs was
observed for patients undergoing TBI.
Our meta-analysis faces specific limitations. First, we did not
search for unpublished studies, and we imposed limits on the
computerized literature search, such as publication in the
English language. However, the likelihood of publication bias in
our results is small and not statistically significant. Secondly, we
observed a very large heterogeneity among the studies. We can
suggest various explanations for this variability, such as study
design, NHL histology, period of recruitment, duration of
follow-up, geographical and genetic variations, and therapies
utilized, but we were unable to account for all these variables.
Moreover, studies included in our analysis recruited patients
over an extended time period (1935–2004), and great changes
occurred in therapeutic regimes during this time. Furthermore,
when we carried out the analysis for risks for specific cancer
types, we found that tumors were coded according to different
revisions of the International Classification of Diseases and
grouped in categories that were not always homogeneous.
The strengths of our study include the use of rigorous
systematic review and meta-analysis techniques to retrieve and
pool data. We incorporated diverse data sources, including data
from observational studies, which may obviate the risk that
Figure 5. Forest plot of relative risk of secondary malignancy in non-Hodgkin’s lymphoma survivors according to exposure to total body irradiation (TBI).
Squares represent the relative risk of each single study (size of the square reflects the study-specific statistical weight); horizontal lines represent 95%
confidence intervals (CIs); diamonds represent the pooled estimates, based on the random-effects meta-analysis of the studies, with corresponding 95% CIs.
The study by Guadagnolo et al. [80] was included among studies that provided an estimate of relative risk for patients without exposure to TBI because
only six patients (6%) received extended-field radiotherapy or low-dose TBI. F, female; M, male; CT, data from clinical trials; HB, data from hospital- or
specialist center-based studies; PB, data from population-based studies.
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clinical trial results may not be generalized to wider groups of
patients [88]. Finally, our estimates of pooled RR for all and
solid SMNs were substantially robust across sensitivity analyses.
Several explanations may account for our demonstration of a
higher overall risk of developing SMNs in NHL survivors in
comparison with the general population. First, risk of therapy-
associated effects in NHL survivors may contribute to increased
RR. It is well known that an excess risk for bladder cancer and
acute nonlymphocytic leukemia in NHL survivors is associated
with alkylating agent therapy [13, 14, 16]. This
chemotherapeutic agent produces DNA damage, and several
DNA lesions are mutagenic, contributing to cellular
transformation [89]. In our meta-analysis, we found a
significant association between risk for SMNs and alkylating
treatment.
The relationship between radiation therapy and SMNs is not
completely clarified. Radiation therapy could trigger a
multistage mechanism of carcinogenesis, significantly
increasing the risk for specific types of tumors [34]. We did not
find a positive significant association with SMNs, but our
analysis did not consider dose, field size, treatment site, and
patient age. Previous studies suggest that low-dose TBI
followed by salvage chemotherapy including alkylating agents
may have synergistic leukemogenic effects [23, 32]. In our
analysis of all malignancies, including the data on TBI
treatment resulted in a positive association with the increase of
pooled RR for SMNs.
In addition to late effects of cancer therapy, other factors
such as genetic instability may play simultaneous and causal
roles [32, 89]. Friedman et al. [90] studied the increased risk for
cancer among siblings of long-term childhood cancer survivors
and discovered a statistically significant risk of 1.8 for siblings
of NHL probands. In contrast, Landgren et al. [91] did not
observe an excess of risk for SMNs among NHL patients with
positive family histories of cancer with respect to patients
lacking the family history. The contribution of shared
environmental influences may be a third explanation for the
high RR observed. For example, smoking is an important
environmental risk factor for lung cancer, and several studies
have found that patients treated for lymphoma with history of
smoking had a greater risk for the development of lung cancer
[92, 93]. Furthermore, Moser et al. [72] in a multivariate
analysis of occurrence of SMNs have highlighted the role of
tobacco use as an additional risk factor for developing SMNs, as
well as of CHOP-like chemotherapy and age.
Some studies argued that the risk for SMNs after NHL
appeared to be age related [18, 72, 77, 85]. We found that a
younger age at NHL diagnosis was significantly associated with
the risk for SMNs for solid tumors, while the RR for all
malignancy increased but was not statistically significant. In
contrast, a longer follow-up could allow the emergence of
neoplasms with long latencies. We also consider other age-
related explanations for our observation, such as the higher
susceptibility of children to the mutagenic effects of therapy
and the prevalence of cell proliferation during the early stages
of development [94].
In conclusion, to the best of our knowledge, this is the first
meta-analysis of SMNs in NHL survivors. Our results
demonstrate that these patients experience a higher risk for
SMNs than the general population and stressed the possible
carcinogenic effect of chemotherapy and combined-modality
therapy. To clarify the underlying mechanisms involved, it
would be necessary to obtain more information on the
treatments and dose schedule used. Additionally, it is
important to consider the complexity of a study addressing
possible interactions with genetic susceptibility and
environmental exposures.
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